Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hudecek

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Nature|September 24, 2025
Boosting immune cells to combat cancer using CRISPR engineering and large-scale in vivo testingMichael Hudecek
Blood|June 30, 2022
Highjacking myeloma's niche with beefed-up CAR-TsMichael Hudecek, Hermann Einsele
Cancer Immunology Research|January 12, 2023
Engineering CD20 CARs with a TwistLukas Scheller, Michael Hudecek
Current Opinion in Genetics & Development|June 30, 2018
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon systemMichael Hudecek, Zoltán Ivics
Blood|October 1, 2016
Myeloma CARs are rolling into the clinical arenaMichael Hudecek, Hermann Einsele
Med (New York, N.Y.)|May 19, 2022
The era of in vivo T cell engineeringGustavo Campos Ramos, Michael Hudecek
Blood|August 1, 2020
What is the future of immunotherapy in multiple myeloma?Leo Rasche, Michael Hudecek, Hermann Einsele
Current Protocols in Immunology|March 10, 2020
Antibody-Based CAR T Cells Produced by Lentiviral TransductionSabrina Prommersberger, Michael Hudecek, Thomas Nerreter
Blood|November 30, 2023
CAR T-cell therapy in multiple myeloma: mission accomplished?Leo Rasche, Michael Hudecek, Hermann Einsele
Best Practice & Research. Clinical Haematology|June 19, 2018
CARs and other T cell therapies for MM: The clinical experienceSophia Danhof, Michael Hudecek, Eric L Smith
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Nature|September 24, 2025
Boosting immune cells to combat cancer using CRISPR engineering and large-scale in vivo testingMichael Hudecek
Blood|June 30, 2022
Highjacking myeloma's niche with beefed-up CAR-TsMichael Hudecek, Hermann Einsele
Cancer Immunology Research|January 12, 2023
Engineering CD20 CARs with a TwistLukas Scheller, Michael Hudecek
Current Opinion in Genetics & Development|June 30, 2018
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon systemMichael Hudecek, Zoltán Ivics
Blood|October 1, 2016
Myeloma CARs are rolling into the clinical arenaMichael Hudecek, Hermann Einsele
Med (New York, N.Y.)|May 19, 2022
The era of in vivo T cell engineeringGustavo Campos Ramos, Michael Hudecek
Blood|August 1, 2020
What is the future of immunotherapy in multiple myeloma?Leo Rasche, Michael Hudecek, Hermann Einsele
Current Protocols in Immunology|March 10, 2020
Antibody-Based CAR T Cells Produced by Lentiviral TransductionSabrina Prommersberger, Michael Hudecek, Thomas Nerreter
Blood|November 30, 2023
CAR T-cell therapy in multiple myeloma: mission accomplished?Leo Rasche, Michael Hudecek, Hermann Einsele
Best Practice & Research. Clinical Haematology|June 19, 2018
CARs and other T cell therapies for MM: The clinical experienceSophia Danhof, Michael Hudecek, Eric L Smith
Pageof 14